Reliable Active Pharmaceutical Ingredient Manufacturer Supporting Global Healthcare

Nintedanib (CAS 656247-17-5, BIBF 1120, Ofev®, Vargatef®) is a small molecule kinase inhibitor used in the treatment of idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease, and certain types of cancer including non-small cell lung cancer. Structurally, Nintedanib features an indole core with a methyl piperazinyl acetamide substituent and a methylamino carbonyl phenyl group.

Baloxavir (CAS 1985605-59-1, baloxavir acid, BXA, S-033447) is a first-in-class cap-dependent endonuclease inhibitor indicated for the treatment of acute uncomplicated influenza in patients aged 12 years and older who have been symptomatic for no more than 48 hours. Structurally, Baloxavir features a unique bicyclic core with a difluorinated benzothiepine ring system fused to a triazatricyclic dione scaffold.

Luvixasertib (CFI-402257) is a highly selective, orally bioavailable small-molecule inhibitor of threonine tyrosine kinase (TTK), also known as monopolar spindle 1 (Mps1). TTK/Mps1 is a dual-specificity protein kinase critical for the spindle assembly checkpoint (SAC) during mitosis. Structurally, Luvixasertib has the CAS number 1610759-22-2 and a molecular weight of approximately 477 g/mol.

Ivosidenib (AG-120) is an orally active, potent, selective, and reversible inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1) enzyme. Structurally, Ivosidenib has the molecular formula C₂₈H₂₂ClF₃N₆O₃ and a molecular weight of 582.96 g/mol. The molecule contains a pyrrolidine-2-carboxamide core with a 4-cyanopyridin-2-yl substituent at the N1 position, a (5-fluoropyridin-3-yl) group at the N-acyl position, and a (2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl side chain.

Etripamil (MSP-2017) is a short-acting L-type calcium-channel antagonist designed for intranasal administration in the treatment of paroxysmal supraventricular tachycardia (PSVT). Structurally, Etripamil has the molecular formula C₂₇H₃₆N₂O₄ and a molecular weight of 452.59 g/mol. The molecule contains a central methyl 3-(2-{(4S)-4-cyano-4-(3,4-dimethoxyphenyl)-4-(propan-2-yl)butylamino}ethyl)benzoate core, featuring a chiral (4S)-configured cyano-dimethoxyphenyl-butyl amine moiety linked to a methyl benzoate via an ethylamino bridge.

Ledipasvir (GS-5885) is a direct-acting antiviral (DAA) medication used in combination with sofosbuvir (under the trade name Harvoni®) for the treatment of chronic hepatitis C genotype 1 infection. Structurally, Ledipasvir is a complex benzimidazole derivative featuring a molecular formula of C₄₉H₅₄F₂N₈O₆ and a molecular weight of 889.0 g/mol.